tirzepatide in mash for Metabolic Dysfunction–Associated Steatohepatitis (MASH) & Uptick GLP1 Use Comparative anti-fibrotic efficacy of resmetirom,

Wolffenbuttel BHR, Heiner-Fokkema MR, Green R, et al

We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology. In two other clinical trials, funded by pharmaceutical companies, which were not included in the meta-analysis due to methodological differences, the drug responses were similar between carriers and non-carriers

doi: 10.1055/s-0043-117893 77 StamatouliABedoyaPYavuzS

We extend our care beyond the city limits, welcoming patients from Northgate, Manitou Springs, Monument, and Woodland Park

While these findings are intriguing, the leap from controlled laboratory settings to the complex biological environment of the human body is significant and uncertain